GlassScriptPhysician profile
Kayla M Cook
NPI 1649822586
$2,536.94
in general payments reported to CMS, 2019-2025
24 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $817 · 2022: $158 · 2023: $646 · 2024: $559 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.39 | 2021-2024 | |
| Abbott Laboratories | $474.40 | 2023-2025 | Proclaim, Eterna |
| Collegium Pharmaceutical, INC. | $392.02 | 2022-2025 | Xtampza |
| Boston Scientific Corporation | $159.02 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Ferring Pharmaceuticals INC. | $153.66 | 2021 | |
| Merck Sharp & Dohme LLC | $134.44 | 2021 | |
| Relievant Medsystems, INC. | $127.18 | 2022-2023 | Intracept |
| Painteq LLC | $90.08 | 2024 | Painteq |
| Vertex Pharmaceuticals Incorporated | $65.60 | 2024-2025 | |
| Averitas Pharma INC. | $57.33 | 2024 | Qutenza |
| Organon LLC | $43.70 | 2021 | |
| Amneal Pharmaceuticals LLC | $43.12 | 2023 | Lyvispah |
| Emd Serono, INC. | $39.52 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.24 | 2022-2025 | Relistor |
| Spr Therapeutics, INC | $27.67 | 2023-2024 | Sprint Pns System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $26.95 | 2023 | |
| Tonix Medicines, INC. | $20.35 | 2025 | Tonmya |
| Xeris Pharmaceuticals, INC. | $19.78 | 2024 | Keveyis |
| Scilex Pharmaceuticals INC. | $19.72 | 2022 | |
| Vertos Medical, INC. | $16.92 | 2023 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $14.96 | 2022 | |
| International Rehabilitative Sciences, INC | $14.72 | 2023 | Rs 4i Plus Sequential Stimulator |
| Ibsa Pharma INC. | $13.72 | 2025 | Tirosint, Licart, Flector |
| Myovant Sciences INC. | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.